Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
出版年份 2022 全文链接
标题
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
作者
关键词
-
出版物
BREAST
Volume 66, Issue -, Pages 169-177
出版商
Elsevier BV
发表日期
2022-10-18
DOI
10.1016/j.breast.2022.10.007
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
- (2022) F. Marmé et al. ANNALS OF ONCOLOGY
- Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer
- (2022) Neelima Vidula et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
- (2022) Laura Spring et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)
- (2022) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
- (2022) Hope S. Rugo et al. npj Breast Cancer
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- Targeting Trop-2 in solid tumors: future prospects
- (2019) Saif Zaman et al. OncoTargets and Therapy
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
- (2019) Koji Haratani et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy
- (2018) Soyoung Son et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
- (2018) Tomomi Nakayama Iwata et al. MOLECULAR CANCER THERAPEUTICS
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
- (2017) Jodi A McKenzie et al. JNCI-Journal of the National Cancer Institute
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
- (2017) Jodi A McKenzie et al. JNCI-Journal of the National Cancer Institute
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety
- (2015) Penelope M Drake et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Dynamics of Inter-heavy Chain Interactions in Human Immunoglobulin G (IgG) Subclasses Studied by Kinetic Fab Arm Exchange
- (2014) Theo Rispens et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- Identification of novel targets for breast cancer by exploring gene switches on a genome scale
- (2011) Ming Wu et al. BMC GENOMICS
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
- (2009) Alexander Stein et al. Therapeutic Advances in Medical Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started